Advertisement

Topics

Latest Plavix NewsRSS

23:01 EST 21st November 2017 | BioPortfolio

Long-term Canakinumab Treatment Lowering Inflammation Independent of Lipid Levels for Residual Inflammatory Risk Benefit – Personalized Medicine for Recurrent MI, Strokes and Cardiovascular Death

Long-term Canakinumab Treatment Lowering Inflammation Independent of Lipid Levels for Residual Inflammatory Risk Benefit – Personalized Medicine for Recurrent MI, Strokes and Cardiovascular Death   Reporter: Aviva Lev-Ari, PhD, RN   Major findings from the trial were presented earlier this year. The trial was designed to test whether canakinumab, which lowers inflammation independe...

CrownBio's Translatable FATZO Model Utilized in Eli Lilly's Preclinical Type 2 Diabetes Research Programs

SANTA CLARA, Calif., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announces the publication of two new papers. These joint public...

Dog Ownership Linked to Lower Mortality

Study shows that dog owners had a lower risk of death due to cardiovascular disease or to other causes

Study: More ‘good’ cholesterol doesn’t reduce CVD risk if ‘bad’ cholesterol stays same

New research suggests greater amounts of high-density lipoprotein (HDL)

BergaMet NA Supplements Coming Soon to VitaBeauti.com

BergaMet NA’s bergamot-based cardiovascular health supplements will soon be available on health, wellness and beauty product e-commerce site VitaBeauti.com. BOCA RATON, Fla. (PRWEB) November 20, 2017 BergaMet NA’s bergamot-based cardiovascular health supplements will soon be available on health, wellness and beauty product e-commerce site VitaBeauti.com. A bergamot is a citrus fruit thought ...

AMPK activator reduces glucose level in type 2 diabetes in phase 2a trial

A novel AMP-activated protein kinase activator showed glucose reduction and decreased cardiovascular risk factors in people with type 2 diabetes in a phase 2a trial, according to a press release from the drug’s developer.The first-in-class drug (O304, Betagenon/Baltic Bio) activates AMP-activated protein kinase (AMPK), which regulates energy balance. By activating this protein, the researchers a...

Research suggests pooches are heart-healthy pets

Owning a dog could be linked to a decreased risk of

Ncardia Announces Completion of €10.5M Investment Round

Stem cell technology innovator continues rapid growth, plans further global expansion to become the global leader in hiPSC-based drug discovery & development solutions Ncardia, an emerging drug discovery and development stem cell technology company whose mission is to deliver cardiac and neural solutions based on its best-in-class human induced plu...

Amish Mutation Protects Against Diabetes and May Extend Life

Amish men and women who carried a genetic mutation appeared to be in better cardiovascular health and had longer telomeres, a barometer of longevity.

LUMEDX to Showcase Leading Cardiovascular Imaging and More at RSNA 2017

LUMEDX Corporation, a cardiovascular data intelligence and information systems (CVIS) company, will present the latest in CV imaging, data management and next generation analytics solutions at the 103rd Scientific Assembly and Annual Meeting of the Radiological Society of North America this month (Booth #6235). LUMEDX says that they will showcase ...

ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting

WESTMINSTER, Colo., Nov. 16, 2017 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the European Patent Office’s issuance of a patent (EPO # 2515899) on methods of treating cardiovascular disease and conditions with a thiol-substi...

Physician: Public education initiatives needed to combat pregnancy-related heart problems

As a specialist in women’s

Jardiance reduced risk of cardiovascular death in adults with type 2...

Ingelheim, Germany : New data showed that empagliflozin reduced the risk of cardiovascular death compared with placebo when added to standard of care in adults with type 2 diabetes and peripheral artery disease. These results, from a post-hoc analysis of the landmark EMPA-REG OUTCOME trial, were shared as an oral presentation on behalf of Boehringer Ingelheim and Eli Lilly and Company at the Ameri...

Global Cardiovascular Devices Market Research Report Forecast 2017 to 2021 [Report Updated: 30102017] Prices from USD $2800

The Global Cardiovascular Devices Market Research Report Forecast 20172021 is a valuable source of insightful data for business strategists. It provides the Cardiovascular Devices industry overview with growth analysis and historical futuristic cost, revenue, demand and supply data as applicable. The research analysts provide an elaborate description of the value chain and its distributor analy...

HIV patients less likely to be prescribed aspirin, statins despite increased cardiovascular risk

People with

Hypertrophic Cardiomyopathy Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $2000

Hypertrophic Cardiomyopathy Pipeline Review, H2 2017SummaryGlobal Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypertrophic Cardiomyopathy Pipeline Review, H2 2017, provides an overview of the Hypertrophic Cardiomyopathy Cardiovascular pipeline landscape.Hypertrophic cardiomyopathy HCM is a disease in which the heart muscle myocardium becomes abnormally thick hype...

Amgen's Repatha Reduces Cardiovascular Events in Patients with a History of Heart Attacks

Data from Amgen's Fourier study supports the use of Repatha to reduce the risk of recurrent cardiovascular events in patients with a history of multiple heart attacks.

Consumption of nuts may cut risk of heart disease by 20%

People who regularly eat nuts have a reduced risk of

Novartis Treatment Reduced Cardiovascular Risk By 25 Percent In Trial

NewsThe phase III results and analysis suggest that in the future, physicians may be able to identify patients who can achieve the greatest cardiovascular benefit from long-term canakinumab treatment.

Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular Risk

BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 14, 2017 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced data analysis orally presented today at the American Heart Association (AHA) 2017 Scientific Sessions in Anaheim, California. The oral presentat...

Amgen's New Analyses Show Repatha Significantly Reduced Cardiovascular Events in Patients With Pe...

These results highlight Repatha's ability to reduce the residual risk for CV events particularly in high-risk patients with limited treatment options.

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

Jardiance® reduced risk of cardiovascular death in adults with type 2 diabetes and peripheral artery disease

Spanish Biotech Gets €2.4M to Spot Myocardial Infarction Before it’s Too Late

GlyCardial Diagnostics believes it has the technology to prevent premature myocardial infarctions, 80% of which are preventable. Barcelona-based GlyCardial Diagnostics is a biotech, which spun-out from the Catalan Institute of Cardiovascular Science. The startup focuses on the development of an in vitro ... This awesome article Spanish Biotech Gets €2.4M to Spot Myocardial Infarction Before it...

Update on Postpartum Hemorrhage

In the United States, postpartum hemorrhage accounts for 11.4% of maternal deaths, the fourth most common cause after cardiovascular diseases, non-cardiovascular diseases, and infection; worldwide, it is the leading cause of maternal mortality. This feature will discuss the latest treatments for managing postpartum hemorrhage.

Hormone Replacement: Have We Made Progress Since WHI?

Vaginal estrogen may improve vaginal symptoms of menopause and does not increase the risk for endometrial cancer, stroke, or cardiovascular disease.

Quick Search
Advertisement
 

review and buy Plavix market research data and corporate reports here